-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $338

Benzinga·11/02/2026 12:40:02
Diffusion vocale
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $290 to $338.